Skip to main content

Regulatory and Washington

  • NCPA, NDPA praise unanimous passage of PBM transparency bill by N.D. state assembly

    ALEXANDRIA, Va. — The National Community Pharmacists Association on Wednesday joined the North Dakota Pharmacy Association in support of a pharmacy benefit manager transparency bill that was passed by the state assembly by a vote of 93-0 on Feb. 25. 

  • Nutritional Magnesium Association critiques recent U.S. Preventive Services Task Force report

    LOS ANGELES — The Nutritional Magnesium Association on Wednesday noted magnesium is an essential nutrient that helps absorb necessary nutritional supplements like vitamin D or calcium in response to a recent U.S. Preventive Services Task Force report that suggested supplementing with these ingredients may not help prevent bone fractures in postmenopausal women, while also increasing the risk of kidney stones. 

  • CVS care-management services subsidiary wins URAC accreditation

    WOONSOCKET, R.I. — Washington-based healthcare accrediting organization URAC has given a subsidiary of CVS Caremark case management accreditation, valid through March 1, 2016, CVS said Wednesday.

    CVS said Accordant Health Services met URAC's standards, which require companies to establish processes to assess, plan and implement case management interventions.

  • Actavis seeks approval for testosterone-replacement gel

    PARSIPPANY, N.J. — Drug maker Actavis is challenging the patent for a drug used to treat testosterone deficiency or absence in men, the company said.

    Actavis, formerly known as Watson Pharmaceuticals, said it had filed a regulatory approval application with the Food and Drug Administration for a generic version of Endo Pharmaceuticals' Fortesta (testosterone) gel in the 10 mg-per-0.5 g strength.

  • Senators encourage GAO to investigate ways to collaborate on prescription drug abuse

    WASHINGTON — Several senators have requested that the Government Accountability Office look for ways to coordinate the efforts of law enforcement and public health agencies at various levels and nonprofit organizations to address prescription drug abuse.

  • GPhA defends patent settlements as Supreme Court date nears

    NEW YORK — The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

    The case, FTC v. Actavis, will go before the high court on March 25 and may decide the future of patent settlements between branded and generic drug companies. The Generic Pharmaceutical Association filed an amicus brief with the court last week defending the settlements as beneficial to consumers.

  • NCPA submits comments to CMS over wide range of issues

    ALEXANDRIA, Va. — The National Community Pharmacists Association on Friday submitted written comments urging the Centers for Medicare and Medicaid Services to take action on a wide range of what NCPA characterizes as "anti-patient, anti-pharmacist practices," the association announced. 

  • FDA accepts application for NSAID painkiller

    PHILADELPHIA — The Food and Drug Administration has accepted a regulatory application for a new painkiller from Iroko Pharmaceuticals, the drug maker said Monday.

    Iroko is seeking approval for a lower-dose, submicron diclofenac, a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain in adults.

X
This ad will auto-close in 10 seconds